These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


627 related items for PubMed ID: 26272765

  • 1. Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
    Wang J, Lu Z, Wang J, Cui M, Yeung BZ, Cole DJ, Wientjes MG, Au JL.
    J Control Release; 2015 Oct 28; 216():103-10. PubMed ID: 26272765
    [Abstract] [Full Text] [Related]

  • 2. Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.
    Wang J, Lu Z, Yeung BZ, Wientjes MG, Cole DJ, Au JL.
    J Control Release; 2014 Mar 28; 178():79-85. PubMed ID: 24462901
    [Abstract] [Full Text] [Related]

  • 3. Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 Xenografts.
    Cui M, Au JL, Wientjes MG, O'Donnell MA, Loughlin KR, Lu Z.
    J Urol; 2015 Jul 28; 194(1):230-7. PubMed ID: 25681288
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures.
    Wong HL, Shen Z, Lu Z, Wientjes MG, Au JL.
    Mol Pharm; 2011 Jun 06; 8(3):833-40. PubMed ID: 21417439
    [Abstract] [Full Text] [Related]

  • 5. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
    Salzano G, Navarro G, Trivedi MS, De Rosa G, Torchilin VP.
    Mol Cancer Ther; 2015 Apr 06; 14(4):1075-84. PubMed ID: 25657335
    [Abstract] [Full Text] [Related]

  • 6. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy.
    Xu C, Liu W, Hu Y, Li W, Di W.
    Theranostics; 2020 Apr 06; 10(7):3325-3339. PubMed ID: 32194871
    [Abstract] [Full Text] [Related]

  • 7. Cationic solid lipid nanoparticles for co-delivery of paclitaxel and siRNA.
    Yu YH, Kim E, Park DE, Shim G, Lee S, Kim YB, Kim CW, Oh YK.
    Eur J Pharm Biopharm; 2012 Feb 06; 80(2):268-73. PubMed ID: 22108492
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
    Zhao X, Li DC, Zhao H, Li Z, Wang JX, Zhu DM, Zhou J, Cen JN.
    Oncol Rep; 2012 Mar 06; 27(3):628-36. PubMed ID: 22200682
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel.
    Liu C, Zhao G, Liu J, Ma N, Chivukula P, Perelman L, Okada K, Chen Z, Gough D, Yu L.
    J Control Release; 2009 Dec 16; 140(3):277-83. PubMed ID: 19699770
    [Abstract] [Full Text] [Related]

  • 12. Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel.
    Yu H, Xu Z, Chen X, Xu L, Yin Q, Zhang Z, Li Y.
    Macromol Biosci; 2014 Jan 16; 14(1):100-9. PubMed ID: 23966347
    [Abstract] [Full Text] [Related]

  • 13. Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
    Luan X, Rahme K, Cong Z, Wang L, Zou Y, He Y, Yang H, Holmes JD, O'Driscoll CM, Guo J.
    Eur J Pharm Biopharm; 2019 Apr 16; 137():56-67. PubMed ID: 30779980
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z, Paul BT, Craft B, ElShamy WM.
    Breast Cancer Res; 2015 Jan 13; 17(1):5. PubMed ID: 25583261
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cluster of Differentiation 44 Targeted Hyaluronic Acid Based Nanoparticles for MDR1 siRNA Delivery to Overcome Drug Resistance in Ovarian Cancer.
    Yang X, Iyer AK, Singh A, Milane L, Choy E, Hornicek FJ, Amiji MM, Duan Z.
    Pharm Res; 2015 Jun 13; 32(6):2097-109. PubMed ID: 25515492
    [Abstract] [Full Text] [Related]

  • 18. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
    Hattori Y, Nakamura A, Arai S, Kawano K, Maitani Y, Yonemochi E.
    J Liposome Res; 2015 Jun 13; 25(4):279-86. PubMed ID: 25543847
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cell-penetrating peptide mimicking polymer-based combined delivery of paclitaxel and siRNA for enhanced tumor growth suppression.
    Jang YL, Yun UJ, Lee MS, Kim MG, Son S, Lee K, Chae SY, Lim DW, Kim HT, Kim SH, Jeong JH.
    Int J Pharm; 2012 Sep 15; 434(1-2):488-93. PubMed ID: 22613208
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 32.